In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disease progression or even the participants are unable to tolerate the study drugs. Feasible new techniques for the prognosis and treatment of AML. (A) The https://abbv-744cancertreatmentcl14691.vblogetin.com/37641541/the-2-minute-rule-for-abbv-744-in-the-treatment-of-drug-resistant-cancers